Other recent approvals include capmatinib (approved in May 2020) [141] and tepotinib (approved in February 2021) [142] for metastatic NSCLC patients whose tumors exhibit splice site alterations in MET exon 14, a family of somatic alterations whose diversity and prevalence across diverse tumor types was first published by Foundation Medicine in 2015 [143]. Here, MET is linked to non-small cell lung carcinoma.